Mizuho analyst Graig Suvannavejh raised the firm’s price target on Harmony Biosciences to $52 from $42 and keeps an Outperform rating on the shares following last week’s “very successful” investor day. The firm incorporated revenue contributions from EPX-100 in Dravet and Lennox-Gastaut syndromes. It believes Harmony” is on the cusp of a significant company transformation” and sees “multiple reasons” for the stock to move higher over the next 12-24 months.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY: